-
Huadong Medicine Seeks Regular Approval for Elahere in Ovarian Cancer Treatment
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its application for converting conditional to regular approval for Elahere (mirvetuximab soravtansine) has been accepted by the National Medical Products Administration (NMPA). This antibody drug conjugate (ADC) targets folate receptor α (FRα) and represents a significant step forward in the treatment…
-
Takeda Partners with BridGene to Develop Immunology and Neurology Drug Candidates
•
Japan-based Takeda Pharmaceutical Company (NYSE: TAK, TYO: 4502) announced a partnership with US-based BridGene Biosciences, Inc. to discover new small molecule drug candidates for immunology and neurology using BridGene’s chemical proteomics platform, IMTAC. The collaboration aims to advance projects through hit finding and early lead development, with Takeda holding exclusive…
-
Takeda’s Takhzyro Receives EMA Approval for New Administration Form in HAE Patients
•
Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) announced that the European Medicines Agency (EMA) has approved a label extension for Takhzyro (lanadelumab) for subcutaneous administration in adolescents aged 12 and above and adult patients with Hereditary Angioedema (HAE) using a 2 mL pre-filled pen. Drug ProfileTakhzyro is now approved in the…
-
Takeda Reports 4.5% Revenue Growth in First Nine Months of Fiscal Year
•
Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) has released its financial results for the 9-month period ended December 31, 2024. The company reported revenues of JPY 3.53 trillion ($22.4 billion), representing a 4.5% growth at constant exchange rates (CER). Sales jumped 14.6% year-on-year (YOY) due to the growth period and continuous…
-
Takeda to Establish China Innovation Center in Chengdu, Focusing on Digital Health
•
Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) has announced plans to establish the Takeda China Innovation Center (TCIC) within the Chengdu Hi-Tech Industrial Development Zone. The company has reached an agreement with the district’s management committee to develop the center, which will focus on enhancing digital innovation capabilities in China. TCIC:…
-
Takeda and Fudan University’s IMI Launch AI-Based Rare Disease Screening and Diagnosis Project
•
Japan-headquartered Takeda (TYO: 4502) and the Intelligent Medicine Institute (IMI) at Fudan University have jointly launched a project focused on developing a generative artificial intelligence (AI)-based rare disease large language model and assisted screening and diagnosis digital solution. This collaboration aims to enhance the early screening and diagnosis of rare…
-
Aosaikang’s Generic Livtencity Accepted for Review by China’s NMPA
•
China’s Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has revealed that a market filing for its generic version of Japan-based Takeda’s (TYO: 4502) Livtencity (maribavir) has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant step in the potential introduction of a more accessible…
-
HutchMed to Receive Milestone Payment as Takeda’s Fruzaqla Gets Reimbursement Nod in Spain
•
China-based HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) is poised to receive another milestone payment from its partner Takeda (TYO: 4502, NYSE:TAK), following the Japanese firm’s achievement of a national reimbursement recommendation for Fruzaqla (fruquintinib) for patients with previously treated metastatic colorectal cancer (CRC) in Spain. This event marks the…
-
Keros Therapeutics and Takeda Enter Licensing Agreement for Elritercept Development
•
US-based Keros Therapeutics, Inc. (NASDAQ: KROS) has announced a significant licensing agreement with Japan-headquartered Takeda (TYO: 4502) to strengthen the research and development of its late-stage investigational activin inhibitor, elritercept. Elritercept’s Clinical Studies and IndicationsElritercept is currently the subject of two clinical studies, one focusing on myelodysplastic syndromes (MDS) and…
-
Alloy Therapeutics Partners with Takeda on iPSC-Derived CAR-T and CAR-NK Therapies
•
US-based Alloy Therapeutics Inc. has announced a strategic partnership with Japan-headquartered Takeda Pharmaceutical Co., Ltd (TYO: 4502) to develop Takeda’s proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) and iPSC-derived CAR-NK platform (iCAR-NK). This collaboration aims to bolster the development of key therapies targeting solid and hematological…
-
AbbVie’s Elahere Receives EC Approval for FRα-Positive Ovarian Cancer Treatment
•
US-based AbbVie (NYSE: ABBV) has announced the European Commission (EC) approval for its antibody drug conjugate (ADC) Elahere (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. This approval marks Elahere as the first and…
-
GSK Leaves BIO, Joining Other Major Companies in Withdrawing Membership
•
GlaxoSmithKline (GSK; NYSE: GSK), a leading pharmaceutical company based in the UK, has reportedly withdrawn from the US industry trade group Biotechnology Innovation Organization (BIO). This decision follows a similar trend set by Pfizer (NSE: PFIZER), UCB (EBR: UCB), WuXi AppTec (HKG: 2359, SHA: 603259), Takeda (TYO: 4502), and other…
-
ATLATL and Takeda Enter MoU to Collaborate on Early-Stage Drug Development and Innovation
•
ATLATL, an innovation incubator and global life science research and development (R&D) platform, has signed a cooperation memorandum of understanding (MoU) with Takeda (TYO: 4502). This partnership aims to jointly explore opportunities in early development, new technology application, and innovative company empowerment, with a focus on oncology, neuroscience, digestive, and…
-
Takeda Reports 5% YOY Revenue Growth and Upgrades Forecasts for Fiscal 2024
•
Takeda (TYO: 4502) has released its earnings results for the first half of fiscal year 2024, reporting a 5% year-on-year (YOY) increase in global revenues at constant exchange rates (CER), reaching JPY 2.38 trillion (USD 15.63 billion). The core operating profit margin expanded to 30.2%, marking a 2.2 percentage point…
-
HutchMed to Receive $20 Million Milestone Payment from Takeda for Fruzaqla Sales
•
China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) is poised to receive a USD 20 million milestone payment from its Japanese partner Takeda (TYO: 4502; NYSE: TAK), following the achievement of over USD 200 million in sales of Fruzaqla (fruquintinib) for metastatic colorectal cancer (CRC). Fruquintinib, a selective oral inhibitor…
-
Takeda’s Vonicog Alfa Receives NMPA Approval for Von Willebrand Disease Treatment in China
•
Takeda Pharmaceutical Company Limited (TYO: 4502 / NYSE: TAK), a leading Japanese pharmaceutical company, has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for vonicog alfa, a recombinant von Willebrand factor (rVWF), for the on-demand treatment and control of bleeding events in adult patients…
-
Takeda to Slash 1,000 US Jobs as Part of Broader Restructuring Effort
•
Japanese pharmaceutical giant Takeda Pharmaceuticals (TYO: 4502 / NYSE: TAK) has confirmed reports from Nikkei that it is planning to eliminate approximately 1,000 positions in the United States. This move is part of a strategic downsizing that will see the closure of a research facility in San Diego, California, and…
-
Takeda Reports Q1 FY2024 Earnings with Growth in Key Therapies and New Launches
•
Japanese pharmaceutical company Takeda (TYO: 4502, NYSE: TAK) has announced its financial results for the first quarter of fiscal year 2024, ending June 30, 2024. The company reported a 2.1% increase in global sales year-on-year, reaching ¥1,208 billion ($7.85 billion) at constant exchange rates. Takeda’s Growth and Launch Product portfolio,…
-
Takeda Reports 3.7% YOY Revenue Growth in Q1 2023 Fiscal Year with Priority Products Driving Sales
•
Japan-based multinational Takeda (TYO: 4502) has released its financial report for the fiscal year 2023 Q1 period ended June 30, 2023. The company reported revenues that grew at 3.7% year-on-year (YOY) in constant exchange rate terms to JPY 1.058 trillion (USD 7.44 billion). Takeda CEO Costa Saroukos highlighted that priority…
-
Ascentage Pharma Receives USD 100 Million Option Rights Payment from Takeda
•
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has received a USD 100 million option rights payment from its Japanese partner Takeda (TYO: 4502), in accordance with an exclusive option agreement signed earlier last month. In June 2024, Takeda and Ascentage entered into an…
